Granules India

Which are the latest news on Granules India?

Why is Granules India Ltd falling/rising?

As of 05-Sep, Granules India Ltd's stock price is at 847.60, down 0.74%. Despite this decline, the stock has shown strong long-term performance with a year-to-date gain of 41.61% and significant investor interest, indicating a solid market position.

As of 05-Sep, Granules India Ltd's stock price is currently at 847.60, reflecting a decrease of 6.35 points or 0.74%. Despite this recent decline, the stock has shown strong performance over various time frames. For instance, it has increased by 1.27% over the past week and 2.68% over the past month, while year-to-date, it boasts an impressive gain of 41.61%. Over the last year, the stock has surged by 65.21%, significantly outperforming the Sensex, which has declined by 10.21% in the same period.<BR><BR>The stock's recent price drop does not seem to be indicative of underlying weakness, as it is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a generally upward trend in the stock's performance. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 167.43% against the 5-day average, indicating heightened interest in the stock.<BR><BR>Positive factors supporting the stock include high management efficiency, evidenced by a return on capital employed (ROCE) of 16.82%, and a low debt to EBITDA ratio of 1.28 times, which indicates a strong ability to service debt. The company has also reported positive results for the last three consecutive quarters, with a profit after tax of Rs 369.30 crore, reflecting a growth of 41.39%, and record net sales of Rs 1,476.77 crore.<BR><BR>Moreover, institutional holdings are robust at 33.61%, with an increase of 1.29% over the previous quarter, suggesting confidence from more sophisticated investors. Overall, while the stock is experiencing a slight decline at the moment, its long-term performance and recent positive indicators suggest a strong position in the market.

Who are in the management team of Granules India?

The management team of Granules India includes C Krishna Prasad (Chairman & Managing Director), KVS Ram Rao (Joint Managing Director & CEO), and several other directors and executives, bringing diverse expertise to the company. Key members also include Harsha Chigurupati, Uma Devi Chigurupati, and independent directors like Arun Sawhney and Saumen Chakraborty.

The management team of Granules India includes the following key members:<BR><BR>1. **C Krishna Prasad** - Chairman & Managing Director<BR>2. **KVS Ram Rao** - Joint Managing Director & CEO<BR>3. **Harsha Chigurupati** - Executive Director<BR>4. **Uma Devi Chigurupati** - Executive Director<BR>5. **A Arun Rao Akinepally** - Non-Executive & Independent Director<BR>6. **Arun Sawhney** - Non-Executive & Independent Director<BR>7. **Saumen Chakraborty** - Independent Director<BR>8. **Sucharita Rao Palepu** - Independent Director<BR>9. **K B Sankara Rao** - Non-Executive & Non-Independent Director<BR>10. **Chaitanya Tummala** - Company Secretary & Compliance Officer<BR>11. **Kapil Mehan** - Independent Director<BR><BR>This team brings a diverse range of expertise and leadership to the company.

What does Granules India do?

Granules India Ltd is a vertically integrated pharmaceutical company that manufactures Active Pharmaceutical Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Finished Dosage (FD). As of June 2026, it reported net sales of ₹1,477 Cr and a net profit of ₹180 Cr, with a market cap of ₹20,452 Cr.

Overview: <BR>Granules India Ltd is a large-scale vertically integrated company in the Pharmaceuticals & Biotechnology industry, specializing in the manufacturing of Active Pharmaceutical Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Finished Dosage (FD).<BR><BR>History: <BR>Granules India Ltd was founded in March 1991. The latest quarterly results reported are for June 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1,477 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 180 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 20,452 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 32.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.21% <BR>Debt-Equity: 0.11 <BR>Return on Equity: 11.86% <BR>Price to Book: 4.09<BR><BR>Contact Details: <BR>Address: Second Floor Block III, My Home Hub Madhapur Hyderabad Telangana : 500081 <BR>Tel: 91-40-66760000 <BR>Email: investorrelations@granulesindia.com <BR>Website: http://www.granulesindia.com

Who are the peers of the Granules India?

Granules India's peers include Neuland Labs, Piramal Pharma, Acutaas Chemical, Pfizer, Caplin Point Lab, ERIS Lifescience, Astrazeneca Pharma, OneSource Specialty, and Shilpa Medicare. Neuland Labs and Acutaas Chemical show excellent management and growth, while Granules India has good management but below-average growth; Acutaas Chemical leads in 1-year returns at 124.38%, while Granules India has a return of 68.32%.

Peers: The peers of Granules India are Neuland Labs., Piramal Pharma, Acutaas Chemical, Pfizer, Caplin Point Lab, ERIS Lifescience, Astrazeneca Phar, OneSource Speci., and Shilpa Medicare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Neuland Labs., Acutaas Chemical, and Astrazeneca Phar, while Good management risk is found at Granules India, Caplin Point Lab, ERIS Lifescience, and Pfizer. Average management risk is noted for Piramal Pharma and Shilpa Medicare, while OneSource Speci. has Below Average management risk. In terms of Growth, Excellent growth is seen at Neuland Labs. and Acutaas Chemical, while Good growth is noted at Shilpa Medicare. Below Average growth is observed at Granules India, Caplin Point Lab, Piramal Pharma, Pfizer, ERIS Lifescience, and OneSource Speci., and Average growth is seen at Astrazeneca Phar. For Capital Structure, Excellent capital structure is attributed to Neuland Labs., Acutaas Chemical, Pfizer, Granules India, Caplin Point Lab, and Astrazeneca Phar, while Good capital structure is noted for ERIS Lifescience, and Below Average capital structure is found at Piramal Pharma, OneSource Speci., and Shilpa Medicare.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Acutaas Chemical at 124.38%, while the lowest is ERIS Lifescience at -27.88%. Granules India has a 1-year return of 68.32%, which is significantly higher than ERIS Lifescience but lower than Acutaas Chemical. Additionally, ERIS Lifescience and Astrazeneca Phar have negative six-month returns.

How big is Granules India?

As of 31st August, Granules India Ltd has a market capitalization of 20,452.00 Cr, with net sales of 5,632.30 Cr and a net profit of 662.35 Cr reported in the latest four quarters. The company has shareholder's funds of 5,084.99 Cr and total assets of 7,656.10 Cr for the annual period ending in March 2026.

As of 31st August, Granules India Ltd has a market capitalization of 20,452.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Granules India reported net sales of 5,632.30 Cr and a net profit of 662.35 Cr.<BR><BR>For the latest annual period ending in March 2026, the company reported shareholder's funds of 5,084.99 Cr and total assets of 7,656.10 Cr.

Should I buy, sell or hold Granules India Ltd?

Are Granules India Ltd latest results good or bad?

Granules India Ltd's latest results show strong year-on-year revenue growth of 22.04% and record quarterly sales, but a 10.72% decline in net profit and reduced margins raise concerns about profitability sustainability. Overall, the results are mixed, highlighting both growth potential and challenges.

Granules India Ltd's latest results present a mixed picture. In Q1 FY27, the company reported a net profit of ₹179.96 crores, which is a decline of 10.72% compared to the previous quarter. However, this figure shows a significant year-on-year increase of 59.77%, indicating strong growth over the past year.<BR><BR>On the revenue front, net sales reached ₹1,476.77 crores, reflecting a modest quarter-on-quarter growth of 0.42% and a more impressive year-on-year growth of 22.04%. This marks the highest quarterly revenue in the company's history and the seventh consecutive quarter of revenue growth.<BR><BR>Despite the positive sales growth, profitability metrics have faced some challenges. The operating margin decreased to 23.13%, down from 24.16% in the previous quarter, while the PAT margin also contracted to 12.28%. These declines are attributed to increased employee costs and a normalization following an exceptionally strong performance in the previous quarter.<BR><BR>Overall, while the revenue growth is commendable and indicates a solid operational performance, the decline in net profit and margins raises some concerns about the sustainability of profitability in the near term. Investors may want to keep an eye on these trends as the company navigates its growth strategy amid these challenges.

When is the next results date for Granules India Ltd?

The next results date for Granules India Ltd is April 29, 2026.

The next results date for Granules India Ltd is scheduled for April 29, 2026.

Is Granules India technically bullish or bearish?

As of December 1, 2025, Granules India has shifted to a bullish trend with moderate strength, supported by bullish indicators like the MACD and Bollinger Bands, although caution is advised due to mildly bearish monthly MACD and KST signals.

As of 1 December 2025, the technical trend for Granules India has changed from mildly bullish to bullish. The current stance is bullish with moderate strength. Key indicators driving this include a bullish MACD on the weekly chart, bullish Bollinger Bands on both weekly and monthly time frames, and a bullish daily moving average. However, the monthly MACD and KST remain mildly bearish, indicating some caution. The stock has shown a strong performance over the past three years compared to the Sensex, further supporting the bullish outlook.

How has been the historical performance of Granules India?

Granules India has experienced fluctuating net sales and profits, peaking at 4,511.92 Cr in March 2023 before a slight decline by March 2025, while operating profit increased to 958.16 Cr due to reduced raw material costs. The company showed resilience with growth in total assets and improved cash flow from operating activities, despite variations in profit before and after tax.

Answer:<BR>The historical performance of Granules India shows a fluctuating trend in net sales and profits over the years, with a notable increase in recent periods.<BR><BR>Breakdown:<BR>Granules India's net sales peaked at 4,511.92 Cr in March 2023 but slightly declined to 4,481.61 Cr by March 2025. The total operating income followed a similar pattern, reaching 4,511.92 Cr in March 2023 and then decreasing to 4,481.61 Cr in March 2025. The raw material costs decreased significantly from 2,352.65 Cr in March 2023 to 1,724.94 Cr in March 2025, contributing to an operating profit (PBDIT) of 958.16 Cr in March 2025, up from 927.60 Cr in March 2023. However, profit before tax showed fluctuations, with a high of 687.17 Cr in March 2023, dropping to 660.17 Cr in March 2025. The profit after tax also varied, recording 516.60 Cr in March 2023 and 501.52 Cr in March 2025. The company's total assets increased from 4,903.14 Cr in March 2023 to 6,184.73 Cr in March 2025, while total liabilities rose from 4,903.14 Cr to 6,184.73 Cr in the same period. Cash flow from operating activities improved to 866 Cr in March 2025, compared to 738 Cr in March 2023, indicating a positive trend in cash generation. Overall, Granules India has shown resilience in its financial performance, with significant growth in assets and operating profits despite some fluctuations in sales and profits.

Is Granules India overvalued or undervalued?

As of November 6, 2025, Granules India is fairly valued with a PE ratio of 28.14, an EV to EBITDA of 15.28, and a ROCE of 15.74%, making it more attractive compared to peers like Sun Pharma and Divi's Lab, despite a recent stock return of -4.20% against the Sensex, while showing a significant long-term gain of 290.73% over the past decade.

As of 6 November 2025, Granules India has moved from an expensive to a fair valuation grade. The company is currently fairly valued based on its valuation metrics. Key ratios include a PE ratio of 28.14, an EV to EBITDA of 15.28, and a ROCE of 15.74%. <BR><BR>In comparison to its peers, Granules India’s PE ratio is lower than Sun Pharma's 35.02 and Divi's Lab's 79.09, indicating a more attractive valuation relative to these companies. Additionally, while Granules India has a PEG ratio of 0.00, indicating potential for growth, it is worth noting that its dividend yield stands at a modest 0.27%. Despite recent underperformance against the Sensex over the past year, with a stock return of -4.20% compared to the Sensex's 3.65%, the long-term performance over the last decade shows a substantial gain of 290.73%.

Who are the top shareholders of the Granules India?

The top shareholders of Granules India include promoter Krishna Prasad Chigurupati with 31.65%, mutual funds at 12.24%, foreign institutional investors at 13.24%, and Life Insurance Corporation of India as the largest public shareholder with 5.33%. Individual investors collectively own 16.54% of the shares.

The top shareholders of Granules India include the promoters, who hold the majority of the shares. The promoter with the highest holding is Krishna Prasad Chigurupati, owning 31.65% of the company. Additionally, mutual funds hold 12.24% through 28 schemes, while foreign institutional investors (FIIs) have a stake of 13.24% across 150 entities. The highest public shareholder is Life Insurance Corporation of India, which holds 5.33%. Individual investors collectively own 16.54% of the shares.

Has Granules India declared dividend?

Granules India Ltd has declared a 150% dividend, amounting to ₹1.5 per share, with an ex-date of July 30, 2024. The company has shown strong long-term performance, with total returns of 190.17% over the past five years.

Granules India Ltd has declared a 150% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 150%<BR>- Amount per share: 1.5<BR>- Ex-date: Jul-30-2024<BR><BR>Dividend Yield: 0.28%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -8.15%, with a dividend return of 0%, resulting in a total return of -8.15%.<BR><BR>Over the past year, the price return was 13.06%, with a dividend return of 0.32%, leading to a total return of 13.38%.<BR><BR>In the 2-year period, the price return was 87.46%, and the dividend return was 1.02%, giving a total return of 88.48%.<BR><BR>For the 3-year period, the price return was 94.13%, with a dividend return of 1.57%, resulting in a total return of 95.7%.<BR><BR>In the last 4 years, the price return was 61.48%, and the dividend return was 1.66%, culminating in a total return of 63.14%.<BR><BR>Over the past 5 years, the price return was 187.16%, with a dividend return of 3.01%, leading to a total return of 190.17%.<BR><BR>Overall, Granules India has declared a significant dividend, and the total returns over various periods show a strong performance, particularly over the long term, indicating a positive outlook for investors.